ABBVIE INC
ABBVNYSETrading Snapshot
- Day Range
- $284.88 β $290.23
- 52-Week Range
- $190.75 β $302.93
- Volume (shares)
- 8,755,117
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.77B
- Next Earnings
- 2027-02-03
Fundamentals Snapshot
- Annual Revenue
- $61.16B
- Last Q Revenue
- $17.40B
- P/E Ratio
- 48.5
- P/S Ratio
- 7.6x
- EPS (TTM)
- $5.83
- Dividend Yield
- 2.42%
- Dilution (1yr)
- +0.1%
ABBVIE INC
ABBVAbout ABBVIE INC
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal BehΓ§et's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends
One drugmaker's earnings look broken on paper, while the other carries negative equity and a mountain of new debt. Both still hand retirees raises every year, so why would anyone trust them with half a million dollars?

AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year.
AbbVie's dividend yield of 2.4% is solid, but more importantly, it's been growing at an impressive clip. The stock isn't cheap, but it warrants consideration for a long-term portfolio.

Breakfast News: When Tech Wobbles, Dividends Pay
Motley Fool analysts share their favorite dividend stocks as tech stocks wobble.

5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
One stock in this five-name healthcare basket costs more in annual tax than the other four combined, and the IRS treats its payout differently from the rest. Find out which one belongs in your Roth first.

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.

AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
NORTH CHICAGO, Ill., Nov. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026.